Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...
UnitedHealthcare CEO Brian Thompson was shot and killed outside a Manhattan hotel early Wednesday morning in what authorities ...
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
David Ricks, the chair and chief executive of Eli Lilly, speaking at The New York Times’s DealBook Summit, said his $750 ...
Access to psychotherapy has increased substantially among Americans, particularly young adults, a new study has found.
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback